Education
University of Massachusetts - BS, Nursing
Georgetown University - MS, Nursing
Certifications
Registered Nurse
AGACNP
Clinical / Research Interests
Stem Cell Transplant
Immunotherapy
Health Equity
Palliative Care
Biography

Molly Gibbs, NP is an adult gerontology acute care nurse practitioner working in the transplant and cellular therapy program at The GW Medical Faculty Associates (GW MFA). She cares for patients with blood cancers and those undergoing bone marrow transplants.

Gibbs completed her undergraduate studies at the University of Massachusetts - Amherst where she received a Bachelor of Sciences degree in Nursing.  Her career began as a registered nurse in the bone marrow transplant unit at the University of North Carolina at Chapel Hill where she administered cellular products, chemotherapy agents, and developed a deep appreciation for the science of cellular transplantation. During her time at UNC, Gibbs transitioned to the Medical Intensive Care Unit within UNC Hospital where she continued caring for high-risk oncology and general medicine patients.

During the COVID-19 pandemic, Gibbs worked as a critical care nurse traveling to five states to work with the most critically ill patients affected by the virus. Upon graduating from Georgetown University with an AGACNP degree, she returned to the oncology field working in the adult ICU at Memorial Sloan Kettering before returning to the bone marrow transplant specialty.  Gibbs is certified by the American Nurse Credentialing Center and holds both RN and NP licenses in New York and the District of Columbia. 

Gibbs believes that health care is all about the individual, finding a treatment that works best for the patient to restore them to living a healthy life. She is also passionate about palliative care for oncology patients; both symptom management and goal of care discussion. While working with patients undergoing cellular transplantation over the past 8 years she has been inspired by the advancements in the field, such as the ever increasing reach of immunotherapies like CAR T therapy.